REG - GENinCode PLC - CARDIO inCode-Score presentation

GenincodeAnnouncement

01/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240501:nRSA6995Ma&default-theme=true

RNS Number : 6995M  GENinCode PLC  01 May 2024

GENinCode Plc

("GENinCode" or the "Company")

 

CARDIO inCode-Score® presentation at

European Society of Cardiology Preventive Cardiology Congress

 

Oxford, UK. GENinCode Plc (AIM: GENI), the polygenics company focused on the
prevention of cardiovascular disease and ovarian cancer, announces  a
presentation by Kaiser Permanente at the European Society of Cardiology (ESC)
Preventive Cardiology congress in Athens, Greece, on the 'Joint consideration
of low-density lipoprotein cholesterol ("LDL-C") and polygenic risk for
incident coronary heart disease in a multi-ethnic cohort of 48,881
individuals' using CARDIO inCode-Score®.(1)

 

The Kaiser Permanente Division of Research study investigated individuals who
were part of the Northern California Genetic Epidemiology Resource in Adult
Health and Aging (GERA) multi-ethnic population-based cohort. The GERA cohort
followed the membership over an average of 14 years, using CARDIO
inCode-Score® to assess the polygenic risk of coronary heart disease ("CHD")
and the incidence of CHD events in association with LDL-C. A CHD event was
defined as non-fatal heart attack, coronary revascularisation procedures or
CHD death.

 

The study found that LDL-C and polygenic risk are independently associated
with incident CHD, and that CARDIO inCode-Score® identifies individuals at
the highest risk of CHD across LDL-C levels. Whilst all patients with elevated
LDL-C ought to be treated, the data indicated that lipid lowering therapies
may be more effective among those with high polygenic risk, as the number
needed to treat (NNT) to prevent one CHD event was much lower in the high
polygenic risk group. The data also indicated that subjects with a high CARDIO
inCode-Score® should not have LDL-C levels above 130 mg/dL, as their CHD risk
is similar to those with LDL-C =>190 mg/dL and a low polygenic risk.

 

The presentation follows the American Journal of Preventive Cardiology
publication earlier this month indicating individuals with a high polygenic
risk score should be prioritised for lifestyle advice and where appropriate
therapeutic intervention as they will benefit the most. Previous data with
CARDIO inCode-Score® has shown that, for individuals with a high genetic
risk, a favourable lifestyle is associated with a 52% lower rate of CHD
compared with an unfavourable lifestyle.

 

The study underlines the need for 'polygenic risk score' lifetime risk
assessment in conjunction with traditional clinical risk assessment to
optimise preventive care strategies to lower the future risk of CHD. Polygenic
risk assessment can be undertaken in younger people, before conventional
clinical risk factors (such as high LDL-C levels, high blood pressure,
diabetes etc.) have developed and can be combined with conventional risk
scoring in older people. By doing this clinicians can better identify those
most likely to benefit from lifestyle and therapeutic intervention.

 

In the UK around 7.6 million people live with heart and circulatory disease,
which causes 25% of all deaths annually. Cardiovacular disease (CVD) can be
reduced by identifying and treating individuals at risk, and the NHS 10 Year
Plan (2019) sets out to address CVD prevention.

 

(1.
 http://www.rns-pdf.londonstockexchange.com/rns/6995M_1-2024-4-30.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/6995M_1-2024-4-30.pdf) )

 

For more information visit www.genincode.com (http://www.genincode.com)

Enquiries:

 

 GENinCode Plc                      www.genincode.com (http://www.genincode.com) or via Walbrook PR
 Matthew Walls, CEO

 Cavendish Capital Markets Limited  Tel: +44 (0)20 7397 8900
 Giles Balleny /Dale Bellis / Michael Johnson
 Dale Bellis / Michael Johnson (Sales)

 Walbrook PR Limited                                                  Tel: 020 7933 8780 or genincode@walbrookpr.com

                                                                    (mailto:genincode@walbrookpr.com)
 Anna Dunphy  / Louis Ashe-Jepson / Phillip Marriage

 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of
cardiovascular disease. Cardiovascular disease is the leading cause of death
and disability worldwide.

 

GENinCode operates business units in the UK, Europe through GENinCode S.L.U,
and in the United States through GENinCode U.S. Inc.

 

GENinCode predictive technology provides patients and physicians with globally
leading preventative care and treatment strategies. GENinCode CE marked
invitro-diagnostic molecular tests combine clinical algorithms and
bioinformatics to provide advanced patient risk assessment to predict
cardiovascular disease.

 

About CARDIO inCode-Score® (CIC-SCORE)

CIC-SCORE is a first in class in-vitro diagnostic test used to assess an
individuals genetic risk of CHD. The test is based on published clinical
evidence amassed over 15 years which, combined with traditional clinical risk
factors, provides a comprehensive risk assessment of CHD for use in primary
preventive care. GENinCode labs process patient DNA samples and deliver the
CARDIO inCode-Score® test results to physicians via an online cloud based
algorithmic (AI) reporting system ('SITAB').

 

CIC-SCORE also addresses the well-recognised need for improvement in the
cardiovascular disease (CVD) standard of care across ethnicities where
individuals from certain racial and ethnic groups face higher risks of CVD.
The CIC-SCORE test provides an improved estimation of an individual's risk of
heart attack over their lifetime, particularly within a 10-year period post
testing when combined with traditional clinical risk assessment. The CIC-SCORE
polygenic risk score enables a major improvement in patient CVD risk
assessment, preventive care and personalised treatment to reduce the incidence
of major adverse cardiovascular events (MACE), such as heart attack.

 

About Cardiovascular Disease (CVD):

Heart and circulatory disease also known as cardiovascular disease (CVD) is
the leading cause of death globally, taking an estimated 17.9 million lives
each year, with Coronary Heart Disease (CHD) representing the leading
cause of death for men, women, and people of most racial and ethnic groups
in the United States. CVD is a group of disorders of the heart and blood
vessels that include coronary heart disease, cerebrovascular disease,
rheumatic heart disease and other conditions. More than four out of five CVD
deaths are due to heart attacks and strokes, and one third of these deaths
occur prematurely in people under 70 years of age. By 2030 the global cost
of CVD is set to rise from approximately US$863 billion in 2010 to US$1,044
billion and is both a major health issue and global economic burden.

 

Cardiovascular disease, causes a quarter of all deaths in the UK and is the
largest cause of premature mortality in deprived areas and is the single
biggest area where the NHS can save lives over the next 10 years. CVD is
largely preventable, through lifestyle changes and a combination of public
health and action on smoking and tobacco addiction, obesity, tackling alcohol
misuse and food reformulation.

 

The most important behavioural risk factors of heart disease and stroke are
unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol.
The effects of behavioural risk factors may show up in individuals as raised
blood pressure, raised blood glucose, raised blood lipids, and overweight and
obesity. These "intermediate risks factors" can be measured in primary care
facilities and indicate an increased risk of heart attack, stroke, heart
failure and other complications.

 

Identifying those at highest risk of CVDs and ensuring they receive
appropriate treatment can prevent premature deaths. Access to noncommunicable
disease medicines and basic health technologies in all primary health care
facilities is essential to ensure that those in need receive treatment and
counselling.

 

The current standard of care for assessing cardiovascular risk is primarily
based on traditional clinical risk factors such as age, sex, smoking, body
mass, blood pressure and cholesterol levels from which individuals are
categorised as being at low, moderate or high risk of a CVD event. This
categorisation is imperfect as CVD events frequently occur in those thought to
be at low or moderate risk. The size of the populations at low or moderate
risk are much larger than those at high or very high risk so whilst the
relative risk of a CVD event may be small, the absolute number of CVD events
in low and moderate risk populations is much greater than the number of events
in higher risk categories.  It is clear that the earlier in life preventative
measures can be put in place the lower the future risk.

 

Clinicians have for many years recognised the importance of prior CVD events
within the families of their patients because genetic factors contribute to
the development of atherosclerosis and a patient's family history has become a
surrogate for their inherited genetic risk. In recent years, with the advances
of genomics, it has proved possible to add genetic profiling to conventional
CVD risk factors, the combination of the two (genetics and conventional
clinical risk factors) enhancing the predictive capability of patient risk
thereby resulting in a personalised and preventative approach to CVD.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBRGDSGXXDGSG